Mary D. Barkley

Find an error

Name: Barkley, Mary D.
Organization: Case Western Reserve University , USA
Department: Department of Chemistry
Title: Professor(PhD)
Co-reporter:Chia-Pin Pan, Pedro L. Muiño, Mary D. Barkley, and Patrik R. Callis
The Journal of Physical Chemistry B 2011 Volume 115(Issue 12) pp:3245-3253
Publication Date(Web):March 3, 2011
DOI:10.1021/jp111925w
Tryptophan (Trp) fluorescence is potentially a powerful probe for studying the conformational ensembles of proteins in solution, as it is highly sensitive to the local electrostatic environment of the indole side chain. However, interpretation of the wavelength-dependent complex fluorescence decays of proteins has been stymied by controversy about two plausible origins of the typical multiple fluorescence lifetimes: multiple ground-state populations or excited-state relaxation. The latter naturally predicts the commonly observed wavelength−lifetime correlation between decay components, which associates short lifetimes with blue-shifted emission spectra and long lifetimes with red-shifted spectra. Here we show how multiple conformational populations also lead to the same strong wavelength−lifetime correlation in cyclic hexapeptides containing a single Trp residue. Fluorescence quenching in these peptides is due to electron transfer. Quantum mechanics−molecular mechanics simulations with 150-ps trajectories were used to calculate fluorescence wavelengths and lifetimes for the six canonical rotamers of seven hexapeptides in aqueous solution at room temperature. The simulations capture most of the unexpected diversity of the fluorescence properties of the seven peptides and reveal that rotamers having blue-shifted emission spectra, i.e., higher average energy, have an increased probability for quenching, i.e., shorter average lifetime, during large fluctuations in environment that bring the nonfluorescent charge transfer state and the fluorescing state into resonance. This general mechanism should also be operative in proteins that exhibit multiexponential fluorescence decays, where myriad other sources of conformational heterogeneity besides rotamers are possible.
Co-reporter:Valerie A. Braz, Mary D. Barkley, Rebecca A. Jockusch, and Patrick L. Wintrode
Biochemistry 2010 Volume 49(Issue 49) pp:
Publication Date(Web):November 19, 2010
DOI:10.1021/bi101480z
Efavirenz (EFV) is a potent nonnucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of AIDS. NNRTIs bind in a hydrophobic pocket located in the p66 subunit of reverse transcriptase (RT), which is not present in crystal structures of RT without an inhibitor. Recent studies showed that monomeric forms of the p66 and p51 subunits bind efavirenz with micromolar affinity. The effect of efavirenz on the solution conformations of p66 and p51 monomers was studied by hydrogen-deuterium exchange mass spectrometry (HXMS) and Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS). HXMS data reveal that five peptides, four of which contain efavirenz contact residues seen in the crystal structure of the RT−EFV complex, exhibit a reduced level of exchange in monomer−EFV complexes. Moreover, peptide 232−246 undergoes slow cooperative unfolding-refolding in the bound monomers, but at a rate much slower than that observed in the p66 subunit of the RT heterodimer [Seckler, J. M., Howard, K. J., Barkley, M. D., and Wintrode, P. L. (2009) Biochemistry 48, 7646−7655]. These results suggest that the efavirenz binding site on p66 and p51 monomers is similar to the NNRTI binding pocket in the p66 subunit of RT. Nanoelectrospray ionization FT-ICR mass spectra indicate that the intact monomers each have (at least) two different conformations. In the presence of efavirenz, the mass spectra change significantly and suggest that p51 adopts a single, more compact conformation, whereas p66 undergoes facile, electrospray-induced cleavage. The population shift is consistent with a selected-fit binding mechanism.
Co-reporter:Valerie A. Braz, Leslie A. Holladay and Mary D. Barkley
Biochemistry 2010 Volume 49(Issue 3) pp:
Publication Date(Web):December 29, 2009
DOI:10.1021/bi901579y
Efavirenz (EFV) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 reverse transcriptase (RT) used for the treatment of AIDS. RT is a heterodimer composed of p66 and p51 subunits; p51 is produced from p66 by C-terminal truncation by HIV protease. The monomers can form p66/p66 and p51/p51 homodimers as well as the p66/p51 heterodimer. Dimerization and efavirenz binding are coupled processes. In the crystal structure of the p66/p51−EFV complex, the drug is bound to the p66 subunit. The binding of efavirenz to wild-type and dimerization-defective RT proteins was studied by equilibrium dialysis, tryptophan fluorescence, and native gel electrophoresis. A 1:1 binding stoichiometry was determined for both monomers and homodimers. Equilibrium dissociation constants are ∼2.5 μM for both p66− and p51−EFV complexes, 250 nM for the p66/p66−EFV complex, and 7 nM for the p51/p51−EFV complex. An equilibrium dissociation constant of 92 nM for the p66/p51−EFV complex was calculated from the thermodynamic linkage between dimerization and inhibitor binding. Binding and unbinding kinetics monitored by fluorescence were slow. Progress curve analyses revealed a one-step, direct binding mechanism with association rate constants k1 of ∼13.5 M−1 s−1 for monomers and heterodimer and dissociation rate constants k−1 of ∼9 × 10−5 s−1 for monomers. A conformational selection mechanism is proposed to account for the slow association rate. These results show that efavirenz is a slow, tight-binding inhibitor capable of binding all forms of RT and suggest that the NNRTI binding site in monomers and dimers is similar.
Co-reporter:James M. Seckler, Kathryn J. Howard, Mary D. Barkley and Patrick L. Wintrode
Biochemistry 2009 Volume 48(Issue 32) pp:
Publication Date(Web):July 13, 2009
DOI:10.1021/bi900790x
Crystal structures and simulations suggest that conformational changes are critical for the function of HIV-1 reverse transcriptase. The enzyme is an asymmetric heterodimer of two subunits, p66 and p51. The two subunits have the same N-terminal sequence, with the p51 subunit lacking the C-terminal RNase H domain. We used hydrogen exchange mass spectrometry to probe the structural dynamics of RT. H/D exchange revealed that the fingers and palm subdomains of both subunits form the stable core of the heterodimer. In the crystal structure, the tertiary fold of the p51 subunit is more compact than that of the polymerase domain of the p66 subunit, yet both subunits show similar flexibility. The p66 subunit contains the polymerase and RNase H catalytic sites. H/D exchange indicated that the RNase H domain of p66 is very flexible. The β-sheet β12-β13-β14 lies at the base of the thumb subdomain of p66 and contains highly conserved residues involved in template/primer binding and NNRTI binding. Using the unique ability of hydrogen exchange mass spectrometry to resolve slowly interconverting species, we found that β-sheet β12-β13-β14 undergoes slow cooperative unfolding with a t1/2 of <20 s. The H/D exchange results are discussed in relation to existing structural, simulation, and sequence information.
Co-reporter:Carl F. Venezia, Brendan J. Meany, Valerie A. Braz and Mary D. Barkley
Biochemistry 2009 Volume 48(Issue 38) pp:
Publication Date(Web):August 28, 2009
DOI:10.1021/bi9010495
The biologically active form of HIV-1 reverse transcriptase (RT) is the p66/p51 heterodimer. The process of maturation of the heterodimer from precursor proteins is poorly understood. Previous studies indicated that association of p66 and p51 is very slow. Three techniques, a pre-steady-state activity assay, intrinsic tryptophan fluorescence, and a FRET assay, were used to monitor the dimerization kinetics of RT. Kinetic experiments were conducted with purified p66 and p51 proteins in aqueous buffer. All three techniques gave essentially the same results. The dissociation kinetics of p66/p51 were first-order with rate constants (kdiss) of ∼4 × 10−6 s−1 (t1/2 = 48 h). The association kinetics of p66 and p51 were concentration-dependent with second-order rate constants (kass) of ∼1.7 M−1 s−1 for the simple bimolecular association reaction. The implications of slow dimerization of p66/p51 for the maturation process are discussed. A reaction-controlled model invoking conformational selection is proposed to explain the slow protein−protein association kinetics.
Co-reporter:James M. Seckler, Mary D. Barkley, Patrick L. Wintrode
Biophysical Journal (5 January 2011) Volume 100(Issue 1) pp:
Publication Date(Web):5 January 2011
DOI:10.1016/j.bpj.2010.11.004
Efavirenz is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) and a common component of clinically approved anti-AIDS regimens. NNRTIs are noncompetitive inhibitors that bind in a hydrophobic pocket in the p66 subunit of reverse transcriptase (RT) ∼10 Å from the polymerase active site. Hydrogen exchange mass spectrometry (HXMS) shows that efavirenz binding reduces molecular flexibility in multiple regions of RT heterodimer in addition to the NNRTI binding site. Of the 47 peptic fragments monitored by HXMS, 15 showed significantly altered H/D exchange rates in the presence of efavirenz. The slow cooperative unfolding of a β-sheet in the NNRTI binding pocket, which was previously observed in unliganded RT, is dramatically suppressed by efavirenz. HXMS also defines an extensive network of allosterically coupled sites, including four distinct regions of allosteric stabilization, and one region of allosteric destabilization. The effects of efavirenz binding extend >60 Å from the NNRTI binding pocket. Allosteric changes to the structural dynamics propagate to the thumb and connection subdomains and RNase H domain of the p66 subunit as well as the thumb and palm subdomains of the p51 subunit. These allosteric regions may represent potential new drug targets.
9H-Carbazole, 3-methyl-
Naphthalene,2-methyl-3-nitro-
1H-Benz[f]indole
Cyclo(L-phenylalanyl-L-phenylalanyl-L-tryptophyl-D-prolyl-O-phosphono-L-t yrosyl-L-threonyl)
CYCLO(L-PHENYLALANYL-L-THREONYL-D-PROLYL-O-PHOSPHONO-L-TYROSYL-L-PHENYLALANYL-L-TRYPTOPHYL)
Cyclo(L-phenylalanyl-L-phenylalanyl-D-prolyl-O-phosphono-L-tyrosyl-L-thre onyl-L-tryptophyl)
CYCLO(L-PHENYLALANYL-L-PHENYLALANYL-D-PROLYL-O-PHOSPHONO-L-TYROSYL-L-TRYPTOPHYL-L-THREONYL)
Cyclo(L-phenylalanyl-L-phenylalanyl-D-prolyl-L-tryptophyl-L-threonyl-O-pho sphono-L-tyrosyl)
CYCLO(L-PHENYLALANYL-L-PHENYLALANYL-O-PHOSPHONO-L-TYROSYL-D-PROLYL-L-TRYPTOPHYL-L-THREONYL)
CYCLO(L-PHENYLALANYL-D-PROLYL-O-PHOSPHONO-L-TYROSYL-L-THREONYL-L-PHENYLALANYL-L-TRYPTOPHYL)